article thumbnail

Building a global supply chain network for clinical trial products

Pharmaceutical Technology

Clinical trial design continues to increase in complexity, and temperature-controlled logistics – in particular cold chain and frozen and associated supply chains – must also advance to keep pace with technological developments. Temperature-controlled clinical trial supply chain.

article thumbnail

Africa: Unleashing the potential of the new superpower in clinical trials

Pharmaceutical Technology

Africa has considerable advantages and opportunities for trialling investigational medicinal products that, if pharma companies can correctly harness, will turn the continent into a superpower for clinical trials. Clinical trials data for Africa Globally, research has found that 62.2%

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Overcoming procurement and supply chain challenges in clinical trials

Pharmaceutical Technology

Running a clinical trial is a complex process that typically involves multiple vendors to obtain everything required, which has been made far more challenging during the global pandemic these past few years. He has spoken at numerous clinical trial conferences worldwide.

article thumbnail

Signant clinical supply chain software offers end-to-end visibility

Outsourcing Pharma

SmartSignals Supplies is designed to help trial teams get a handle on clinical trial supply chain management to avoid delays, waste, and cost overruns.

article thumbnail

Tech innovations that curb complexity, setting clinical trials up for success

Pharmaceutical Technology

There is no denying that trial complexity is continuing to increase. Several factors in recent years have contributed to this rise including more complex trial designs, the rapid adoption of decentralisation stemming from the pandemic, and larger global trials.

article thumbnail

[Webinar] How biotech companies can improve clinical supply planning and distrib…

The Pharma Data

Find out solutions to mitigate the impact from clinical supply chain risk and discover how to improve dynamic drug supply forecasting strategies. Enrolling study subjects, setting up patient randomization and managing drug supply are critical to the success of a clinical trial.

article thumbnail

How direct-to-patient clinical trial models can accelerate speed-to-market

The Pharma Data

Analyzing the benefits and challenges of implementing direct-to-patient services in the clinical supply chain to help meet patient requirements, improve supply chain efficiency and accelerate speed to market.

article thumbnail

Clientpharma Announces Strategic Partnership with Trialcard

Client Pharma

Collaboration provides clinical trial sponsors with access to the world’s most efficient clinical supply processes using a single contract. This will cut supply costs by 50% and reduce clinical supply teams’ efforts by 80%.

article thumbnail

How to cut drug supply costs with seamless forecasting and IRT systems

Pharmaceutical Technology

An accurate drug supply forecast is essential for a successful clinical trial. Without it, sponsors risk a shortage of investigative medicinal product (IMP) for patients, resulting in major trial delays. They begin the trial expecting about a 30 percent overage.

article thumbnail

How to plan for uncertainty while maximizing the efficiency of your clinical sup…

The Pharma Data

Supply chain uncertainty is a challenge every clinical supply chain manager wrestles with – stemming from increasing product demand and quality, the growing complexity of clinical trial designs and a lack of visibility in the supply chain. Clinical Trails

article thumbnail

FDA grants orphan drug designation for Syros’ pancreatic cancer treatment

Pharmaceutical Technology

The Phase I clinical trial that is underway is assessing SY-5609 plus chemotherapy in subjects with pancreatic cancer whose disease has advanced after Folfirinox treatment. .

article thumbnail

GCSG 2020 Virtual Conference

Client Pharma

Client-Pharma is proud to be a Bronze sponsor at this year’s first-ever Global Clinical Supplies Group – GCSG 2020 Virtual Conference. Join us and other professionals September 21-25 for interactive and engaging workshop discussions, developing best practices in clinical trial supply and fun networking events from the comfort of your home or office.

article thumbnail

GCSG 2020 Virtual Conference

Client Pharma

Client-Pharma is proud to be a Bronze sponsor at this year’s first-ever Global Clinical Supplies Group – GCSG 2020 Virtual Conference. Join us and other professionals September 21-25 for interactive and engaging workshop discussions, developing best practices in clinical trial supply and fun networking events from the comfort of your home or office.

article thumbnail

Oxford Biomedica and Beam Therapeutics sign CAR-T deal

The Pharma Data

The agreement also puts in place a three year clinical supply agreement for the two companies. Agreement will utilise Oxford Biomedica's LentiVector platform.

article thumbnail

VTX-801 RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR THE TREATMENT OF WILSON DISEASE

The Pharma Data

Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company, and Pfizer Inc. Pfizer is collaborating with Vivet on the clinical supply of VTX-801 for the Phase 1/2 clinical trial. About GATEWAY – Phase 1/2 Clinical Trial of VTX-801 in Wilson Disease.

article thumbnail

AlgoTherapeutix Receives Regulatory Approval to Initiate Clinical Development of ATX01

The Pharma Data

The trial, which will explore the pharmacokinetics and safety of ATX01 in healthy volunteers, is due to start in January 2021. AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. 15, 2020 07:15 UTC.

article thumbnail

MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference

The Pharma Data

Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development.

article thumbnail

AWS helps Pfizer accelerate drug development and clinical manufacturing

The Pharma Data

company (NASDAQ: AMZN), announced that it is working with Pfizer to create innovative, cloud-based solutions with the potential to improve how new medicines are developed, manufactured, and distributed for testing in clinical trials. Today, Amazon Web Services, Inc.

article thumbnail

Molecular Partners Doses First Cohort in Phase 1 Trial of COVID-19 DARPin(R) Therapeutic Candidate MP0420

The Pharma Data

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / November 23, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that a first cohort of eight healthy volunteers has been dosed in a Phase 1 first-in-human study of MP0420 (ensovibep), a DARPin® therapeutic candidate for the potential treatment and prevention of COVID-19.

Protein 40
article thumbnail

PharmaDrug Enters Definitive Agreement for Acquisition of Sairiyo Therapeutics Inc. Who Recently Received Orphan Drug Designation from FDA for Esophageal Cancer

The Pharma Data

Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases. Toronto, Ontario–(Newsfile Corp.

article thumbnail

Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19

The Pharma Data

Molecular Partners, a global leader in the development of DARPin® therapeutics, will be responsible for the conduct of phase 1 & 2 trials that may lead to emergency use approval; Novartis will be responsible for further development, manufacturing, distribution and commercialization.

Protein 52
article thumbnail

Nordic Nanovector ASA: Results for the Third Quarter 2020

The Pharma Data

Lars Nieba, Interim CEO of Nordic Nanovector, said: “Following the successful interim analysis in August and completion of our private placement in September, we are progressing towards the major value inflection point of three-month top-line data from the PARADIGME clinical study, which is targeted for H2 2021. Trial to be paused pending analysis of data and evaluation of plans for further development. OSLO, Norway , Nov.